Raltegravir as Early Therapy in African-Americans Living With HIV Study (REAL)
|ClinicalTrials.gov Identifier: NCT00667433|
Recruitment Status : Completed
First Posted : April 28, 2008
Last Update Posted : March 3, 2017
David A Wohl, MD
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
David A Wohl, MD, University of North Carolina, Chapel Hill
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Completed|
|Actual Primary Completion Date :||December 2011|
|Actual Study Completion Date :||December 2011|
Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Gilde LR, Wan H, Miller MD, Wenning LA, Teppler H; Protocol 004 Part II Study Team. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):125-33.